Etamsilato Dicynone Una terapia clásica. Muy eficiente. Cumple solucionando muchos eventos hemorrágicos. PERO?????? Que es?. [Uso de etamsilato para reducir el sangrado posoperatorio y el índice de Both methods were based on the oxidation of the cited drugs with cerium (IV) in acid. El etamsilato es un fármaco ampliamente utilizado en medicina veterinaria y su administración intravenosa (IV) e intramuscular (IM) y oral (VO) en diversas.
|Published (Last):||20 June 2011|
|PDF File Size:||5.90 Mb|
|ePub File Size:||11.32 Mb|
|Price:||Free* [*Free Regsitration Required]|
Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: Cancer AND drug name.
Etamsylate | Apollo Pharmaceuticals
Pneumonia AND sponsor name. How to search [pdf]. Etamsilaro these items you should use the filters and not add them to your search terms in the text field. Trials with results Trials without results Clear advanced search filters.
Review by the Competent Authority or Ethics Committee in the country concerned.
EU Clinical Trials Register. Both Female Only Male Only.
IMP with orphan designation in the indication. Trials with results Trials without results. Clear advanced search filters. Date on which this record was first entered in the EudraCT database:.
Title of the trial for lay people, in easily understood, i. Extension study for the follow up of patients with age related macula degeneration who participated in the Fase IV-II clinical trial randomized, simulated and blinded controlled treatment to evaluate safety and efficacy of a drug administered etamsilato via a needle in the eye.
The IMP has been designated in this indication as an orphan drug in the Community. Committee on Advanced therapies CAT has issued a lv for this product.
Search Our Scientific Publications & Authors
Combination product that includes a device, but does not involve an Advanced Therapy. Aged related macula degeneration ARMD. Aged related macula degeneration.
Evaluate the effect of treatment received in the previous clinical trial intravitreal ethamsylate or simulated treatment in improvement of the visual acuity in patients diagnosed with dry or wet aged related macular degeneration disease after a non-interventionist tracking “treated eye” in the clinical trial until the week 48 of the double blinded treatment administration.
Criteria for evaluation of effectiveness -Rate of success of treatment for treated eyes in the 4,16,24,36 weeks after the double blinded treatment with or without second injection or after the open and active treatment of the contralateral eye. Criteria for evaluation of safety: The trial involves single site in the Member State concerned.
Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial. Plans for treatment or care after the subject has ended the participation in the trial if it is different from the expected normal treatment of that condition.